0.00Open0.00Pre Close0 Volume0 Open Interest50.00Strike Price0.00Turnover1005.97%IV-1518.12%PremiumJan 17, 2025Expiry Date46.91Intrinsic Value100Multiplier12DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7252Delta0.0607Gamma0.07Leverage Ratio-0.0735Theta-0.0090Rho-0.05Eff Leverage0.0019Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet